240
Participants
Start Date
May 1, 2025
Primary Completion Date
May 20, 2025
Study Completion Date
July 14, 2025
Sugammadex 1 mg/kg Group
Participants receive 1 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
Sugammadex 2 mg/kg Group
Participants receive 2 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
Sugammadex 4 mg/kg Group
Participants receive 4 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
Pyridostigmine/Glycopyrrolate Group
Participants receive pyridostigmine 0.2 mg/kg and glycopyrrolate 0.01 mg/kg intravenously for reversal of rocuronium-induced neuromuscular blockade.
Wonkwang University hospital, Iksan
Wonkwang University Hospital
OTHER